🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In recent research article, Patel et al. investigate a Phase 1B clinical trial combining Selinexor (KPT-330) & immune checkpoint inhibitor to treat uveal melanoma doi.org/10.36401/JIPO-… #clinicaltrial #phase1 #uvealmelanoma #JIPO Mohamed A Gouda #Selinexor Innovative Oncology Network

Mohamed A Gouda Innovative Oncology Network Watch the video inerview too: youtube.com/watch?v=D9njDj… Aung Naing Jibran Ahmed Yostena Mekhail, MD, PhD @mderbalamd Maria Hafez Carlos Torrado Sewanti Limaye 🇮🇳🇺🇸 Gil Morgan, MD Innovative Oncology Network

MD Anderson and Texas Children's announce a transformational collaboration dedicated solely to pediatric cancer care. This new first-of-its-kind joint venture, which will launch in early 2026, has a single mission: to end #ChildhoodCancer.  Learn more: bit.ly/3X9VtOR

Now published in Cancer Medicine! onlinelibrary.wiley.com/doi/10.1002/ca…

What mediates resistance to antibody drug conjugates? Report Clinical Cancer Research shows that in pts with breast cancer treated with trastuzumab deruxtecan (T-DXd, #HER2 ADC), 32% lost HER2 expression by IHC and another 29% had a decrease in HER2 score. aacrjournals.org/clincancerres/…

Excited to share our new publication in Annals of Oncology! annalsofoncology.org/article/S0923-… Efficacy assessment is important in oncology phase 1 trials. How do we integrate classic and novel endpoints for assessment of efficacy in trial designs? Ignacio Garrido-Laguna Pablo A. Ballesteros J Rodon

Nothing better to see your mentees presenting!!! MD Anderson Cancer Center #AACR25

Great poster presentation by our colleague Mohamed A Gouda. Strong work on MTAP alterations. Congratulations! Camila Braganca Xavier AACR MD Anderson Cancer Center

The first of the three presentations from our ICT fellows batch. Strong work Mohamed A Gouda. Two more days to go! #AACR25 MD Anderson Cancer Center

🚨📣🩸participate on the first global survey on attitudes, practices & barriers to #LiquidBiopsy use among clinical oncologists! 🌍 International Society of Liquid Biopsy It takes just 10 minutes⏰ and it will help to shape the future of cancer care! 👉 docs.google.com/forms/d/e/1FAI…

3/3 poster presentations done and the ICT fellows can call it a day! A privilege to finalize #AACR25 with a hug from the one and only Dr Meric-Bernstam. Carlos Torrado Mohamed A Gouda MD Anderson Cancer Center

All 3 will soon be MDACC faculty! Congrats!!!

Our newest publication in ESMO Open! 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: esmoopen.com/article/S2059-…

Very interesting study!

Excited to share our new publication in CCR on concordance between tissue and plasma DNA testing in the NCI-MATCH trial! The tissue alteration of interest was detected in plasma of 81% of patients with contemporaneous tissue biopsy! Full article link: aacrjournals.org/clincancerres/…

Today at 12 PM you can meet Prof. David Gandara and our Young Committee at our Booth 12401 at #ASCO25 Stop buy to engage nice discussion with leading experts and to discover more about our society! ASCO Carolina Reduzzi Erick Saldanha, MD Roberto Borea, MD Mohamed A Gouda

Here with David Gandara , ISLB CMO, and some amazing members of the ISLB Young Committee! 🙌 Great to meet in person and share ideas 💡on how to keep growing together. Excited for what’s ahead! the best is yet to come! #ASCO25 @Booth12041 Carolina Reduzzi Mohamed A Gouda

Amazing #ASCO25 with the (former & current) ICT team!! MD Anderson Cancer Center Harold Nathan Tan Carlos Torrado Mohamed A Gouda David S. Hong MD

Our review on key advancements in #liquidbiopsy in 2024 is finally out! This work was made possible thanks to the incredible team effort of the International Society of Liquid Biopsy Young Committee. 📰Check it out! ➡️ sciencedirect.com/science/articl…

Great paper from our ISLB Young Committee! A huge effort to keep sharing #LiquidBiopsy knowledge through reviews and editorials after major conferences worldwide. Follow us for more LB updates and insights! 🌍🧬 #ISLB #sciencecommunication